Literature DB >> 3147905

Effect of cholestyramine on plasma cholecystokinin and pancreatic polypeptide levels, and exocrine pancreatic secretion.

I Koop1, A Fellgiebel, H Koop, A Schafmayer, R Arnold.   

Abstract

The effect of acute and long-term administration of cholestyramine, a non-absorbable bile salt binding resin, on exocrine pancreatic secretion, plasma-cholecystokinin (CCK) and plasma-pancreatic polypeptide (PP) was investigated in 10 healthy volunteers. Oral ingestion of 12 g cholestyramine augmented the stimulatory effect of a liquid test meal on plasma-CCK (3.5-fold) and plasma-PP (2-fold). During prolonged treatment with 3 x 12 g cholestyramine daily for 4 weeks, the most pronounced increase in basal hormone levels was observed after 1 day, but progressively decreased during treatment and had normalized after 4 weeks. However, the stimulated plasma-CCK output was still significantly elevated after cessation of treatment, compared with pretreatment values. After acute and chronic cholestyramine administration only stimulated lipase secretion was elevated, whereas trypsin and amylase remained unchanged. It is suggested that removal of bile salts enhances CCK and thereby PP release and pancreatic lipase secretion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147905     DOI: 10.1111/j.1365-2362.1988.tb01050.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  14 in total

Review 1.  Is there a duodenum-pancreas negative feedback? Views: pro and con.

Authors:  D F Magee
Journal:  Int J Pancreatol       Date:  1991-05

2.  Effect of loxiglumide (CR-1505) on bombesin- and meal-stimulated plasma cholecystokinin in man.

Authors:  J B Jansen; M C Jebbink; B R Douglas; C B Lamers
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Protective action of luminal bile salts in necrotizing acute pancreatitis in mice.

Authors:  G Gomez; C M Townsend; D W Green; S Rajaraman; T Uchida; G H Greeley; R D Soloway; J C Thompson
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

4.  Intraduodenal conjugated bile salts exert negative feedback control on gall bladder emptying in the fasting state without affecting cholecystokinin release or antroduodenal motility.

Authors:  N A M van Ooteghem; A Moschetta; J F Rehfeld; M Samsom; K J van Erpecum; G P van Berge-Henegouwen
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

5.  Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids.

Authors:  I Koop; M Schindler; A Bosshammer; J Scheibner; E Stange; H Koop
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

6.  Effect of cholestyramine and cholecystokinin receptor antagonist CR1505 (loxiglumide) on lower esophageal sphincter pressure in man.

Authors:  A A Masclee; J B Jansen; L C Rovati; C B Lamers
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

7.  Dissociation of cholecystokinin and pancreaticobiliary response to intraduodenal bile acids and cholestyramine in humans.

Authors:  I Koop; S Dorn; H Koop; S Witzleb; C Beglinger; A Schafmayer; R Arnold
Journal:  Dig Dis Sci       Date:  1991-11       Impact factor: 3.199

8.  Role of endogenous bile on basal and postprandial CCK release in humans.

Authors:  M Koide; Y Okabayashi; M Otsuki
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

9.  Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones.

Authors:  B J van de Heijning; P C van de Meeberg; P Portincasa; H Doornewaard; F J Hoebers; K J van Erpecum; G P Vanberge-Henegouwen
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

Review 10.  Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes.

Authors:  Morten Hansen; David P Sonne; Filip K Knop
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.